{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:09:37Z","timestamp":1789042177351,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ajpc.2026.101521","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:26:32Z","timestamp":1772526392000},"page":"101521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Association between semaglutide 2.4 mg and risk of cardiovascular events in people with overweight or obesity without atherosclerotic cardiovascular disease in the real-world: The SCORE \u2013 primary prevention study"],"prefix":"10.1016","volume":"27","author":[{"given":"Kim G.","family":"Smolderen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Mena-Hurtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Divino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7858-979X","authenticated-orcid":false,"given":"Joanna","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Gabriel","family":"Smolarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip K.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Nanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpc.2026.101521_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110691","article-title":"Association between obesity, inflammation and insulin resistance: insights into signaling pathways and therapeutic interventions","volume":"200","author":"Suren Garg","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"20","key":"10.1016\/j.ajpc.2026.101521_bib0002","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ajpc.2026.101521_bib0003","first-page":"504","article-title":"Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity","volume":"11","author":"Henning","year":"2021","journal-title":"Am J Cardiovasc Dis"},{"issue":"8","key":"10.1016\/j.ajpc.2026.101521_bib0004","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/eurjpc\/zwae025","article-title":"Obesity and cardiovascular health","volume":"31","author":"Welsh","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"10.1016\/j.ajpc.2026.101521_bib0005","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart association task force on clinical practice guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2026.101521_bib0006","unstructured":"Wegovy (Semaglutide) injection. Prescribing information. Novo Nordisk A\/S, 2025. Accessed October 20, 2025. https:\/\/www.novo-pi.com\/wegovy.pdf."},{"issue":"24","key":"10.1016\/j.ajpc.2026.101521_bib0007","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"10516","key":"10.1016\/j.ajpc.2026.101521_bib0008","doi-asserted-by":"crossref","first-page":"P2257","DOI":"10.1016\/S0140-6736(25)01375-3","article-title":"Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial","volume":"406","author":"Deanfield","year":"2025","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ajpc.2026.101521_bib0009","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1111\/dom.70080","article-title":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: results from the SCORE study (Semaglutide effects on cardiovascular outcomes in people with overweight or obesity in the real world)","volume":"27","author":"Smolderen","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101521_bib0010","doi-asserted-by":"crossref","first-page":"8890","DOI":"10.1038\/s41598-024-58719-y","article-title":"A machine-learning algorithm using claims data to identify patients with homozygous familial hypercholesterolemia","volume":"14","author":"Gu","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpc.2026.101521_bib0011","unstructured":"Komodo Health Inc. Healthcare Map. Accessed October 20, 2025. https:\/\/www.komodohealth.com\/technology\/healthcare-map."},{"issue":"9","key":"10.1016\/j.ajpc.2026.101521_bib0012","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jacc.2017.12.048","article-title":"2017 Cardiovascular and stroke endpoint definitions for clinical trials","volume":"71","author":"Hicks","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ajpc.2026.101521_bib0013","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","year":"2009","journal-title":"Commun Stat Simul Comput"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101521_bib0014","first-page":"141","article-title":"An empirical transition matrix for non-homogenous Markov chains based on censored observations","volume":"5","author":"Aalen","year":"1978","journal-title":"Scand J Stat"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101521_bib0015","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1214\/aos\/1176344198","article-title":"Nonparametric estimation of partial transition probabilities in multiple decrement models","volume":"6","author":"Aalen","year":"1978","journal-title":"Ann Stat"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101521_bib0016","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12874-019-0754-4","article-title":"Methods to adjust for multiple comparisons in the analysis and sample size calculation of randomised controlled trials with multiple primary outcomes","volume":"19","author":"Vickerstaff","year":"2019","journal-title":"BMC Med Res Methodol"},{"issue":"Suppl_3","key":"10.1016\/j.ajpc.2026.101521_bib0017","volume":"152","author":"Smolderen","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2026.101521_bib0018","unstructured":"Plutzky J., Ostrominski J.W., Aroda V.R., et al. Early clinical benefit of semaglutide in adults with overweight or Obesity and cardiovascular disease: a secondary analysis of the SELECT trial. Oral presentation presented at European Congress on Obesity 2025, Malaga, Spain, 13 May 2025. Presentation AD15.04."},{"key":"10.1016\/j.ajpc.2026.101521_bib0019","doi-asserted-by":"crossref","first-page":"E157","DOI":"10.5888\/pcd13.160211","article-title":"Heart disease and Cancer deaths - trends and projections in the United States, 1969-2020","volume":"13","author":"Weir","year":"2016","journal-title":"Prev Chronic Dis"},{"issue":"10440","key":"10.1016\/j.ajpc.2026.101521_bib0020","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ajpc.2026.101521_bib0021","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 Heart Disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.ajpc.2026.101521_bib0022","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","article-title":"Global effect of modifiable risk factors on cardiovascular disease and mortality","volume":"389","author":"Global Cardiovascular Risk","year":"2023","journal-title":"N Engl J Med"},{"issue":"10226","key":"10.1016\/j.ajpc.2026.101521_bib0023","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(19)32008-2","article-title":"Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study","volume":"395","author":"Yusuf","year":"2020","journal-title":"Lancet"},{"issue":"10046","key":"10.1016\/j.ajpc.2026.101521_bib0024","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0140-6736(16)30506-2","article-title":"Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study","volume":"388","author":"O'Donnell","year":"2016","journal-title":"Lancet"},{"issue":"9438","key":"10.1016\/j.ajpc.2026.101521_bib0025","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ajpc.2026.101521_bib0026","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jacc.2018.07.007","article-title":"Cardiovascular health promotion: an issue that can No longer wait","volume":"72","author":"Turco","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2026.101521_bib0027","series-title":"Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: united states, 1960-1962 through 2017-2018","year":"2025"},{"issue":"5","key":"10.1016\/j.ajpc.2026.101521_bib0028","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.mayocp.2016.01.019","article-title":"A systematic review of the prevalence and outcomes of ideal cardiovascular health in US and Non-US populations","volume":"91","author":"Younus","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"25","key":"10.1016\/j.ajpc.2026.101521_bib0029","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ajpc.2026.101521_bib0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014402","article-title":"Incidence and predictors of major adverse cardiovascular events in patients with established atherosclerotic disease or multiple risk factors","volume":"9","author":"Miao","year":"2020","journal-title":"J Am Heart Assoc"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726001157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726001157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:21:03Z","timestamp":1789039263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667726001157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"alternative-id":["S2666667726001157"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101521","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between semaglutide 2.4 mg and risk of cardiovascular events in people with overweight or obesity without atherosclerotic cardiovascular disease in the real-world: The SCORE \u2013 primary prevention study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101521"}}